Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nudemouse model

Takashi Murakami, Arun S. Singh, Tasuku Kiyuna, Sarah M. Dry, Yunfeng Li, Aaron W. James, Kentaro Igarashi, Kei Kawaguchi, Jonathan C. DeLong, Yong Zhang, Yukihiko Hiroshima, Tara Russell, Mark A. Eckardt, Jane Yanagawa, Noah Federman, Ryusei Matsuyama, Takashi Chishima, Kuniya Tanaka, Michael Bouvet, Itaru EndoFritz C. Eilber, Robert M. Hoffman

Research output: Contribution to journalArticle

Abstract

Ewing's sarcoma is a rare and aggressive malignancy. In the present study, tumor from a patient with a Ewing's sarcoma with cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) loss and FUS-ERG fusion was implanted in the right chest wall of nude mice to establish a patient-derived orthotopic xenograft (PDOX) model. The aim of the present study was to determine efficacy of cyclin-dependent kinase 4/6 (CDK4/6) and insulin-like growth factor-1 receptor (IGF-1R) inhibitors on the Ewing's sarcoma PDOX. The PDOX models were randomized into the following groups when tumor volume reached 50 mm3: G1, untreated control; G2, doxorubicin (DOX) (intraperitoneal (i.p.) injection, weekly, for 2 weeks); G3, CDK4/6 inhibitor (palbociclib, PD0332991, per oral (p.o.), daily, for 14 days); G4, IGF-1R inhibitor (linsitinib, OSI-906, p.o., daily, for 14 days). Tumor growth was significantly suppressed both in G3 (palbociclib) and in G4 (linsitinib) compared to G1 (untreated control) at all measured time points. In contrast, DOX did not inhibit tumor growth at any time point, which is consistent with the failure of DOX to control tumor growth in the patient. The results of the present study demonstrate the power of the PDOX model to identify effective targeted molecular therapy of a recalcitrant DOX-resistant Ewing's sarcoma with specific genetic alterations. The results of this study suggest the potential of PDOX models for individually-tailored, effective targeted therapy for recalcitrant cancer.

Original languageEnglish (US)
Pages (from-to)47556-47564
Number of pages9
JournalOncotarget
Volume7
Issue number30
DOIs
StatePublished - Jan 1 2016

Keywords

  • Ewing's sarcoma
  • Linsitinib
  • PDOX
  • Palbocicib
  • Patient-derived orthotopic xenograft

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nudemouse model'. Together they form a unique fingerprint.

  • Cite this

    Murakami, T., Singh, A. S., Kiyuna, T., Dry, S. M., Li, Y., James, A. W., Igarashi, K., Kawaguchi, K., DeLong, J. C., Zhang, Y., Hiroshima, Y., Russell, T., Eckardt, M. A., Yanagawa, J., Federman, N., Matsuyama, R., Chishima, T., Tanaka, K., Bouvet, M., ... Hoffman, R. M. (2016). Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nudemouse model. Oncotarget, 7(30), 47556-47564. https://doi.org/10.18632/oncotarget.9879